Methods for decreasing immune response and treating immune conditions

• US 20070280933A1
• Filed: 04/06/2007
• Published: 12/06/2007
• Est. Priority Date: 05/31/2006
• Status: Active Grant

• Current Assignee: Apollo Endosurgery, Inc. (Boston Scientific Corporation)
• Original Assignee: Lpath Inc. (Boston Scientific Corporation)
• Inventors: Sabbadini, Roger A.
• Granted Patent: US 7,862,812 B2
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 39/39591 Stabilisation, fragmentation
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/3076 against structure-related tumour-associated moieties
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).

Claims

1. A method of decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid.

2. The method of claim 1 wherein the bioactive lipid is a sphingolipid or sphingolipid metabolite.

3. The method of claim 1 wherein the bioactive lipid is a lysolipid or lysolipid metabolite.

4. The method of claim 3 wherein the lysolipid is S1P, LPA or a variant of S1P or LPA.

5. The method of claim 1 wherein the agent is an antibody or antibody fragment.

6. The method of claim 5 wherein the antibody is a monoclonal antibody.

7. The method of claim 6 wherein the monoclonal antibody is a humanized monoclonal antibody.

8. The method of claim 1 where the agent is a receptor fragment, ion channel fragment, aptamer or the domain of an enzyme that binds a bioactive lipid

9. The method of claim 1 wherein the animal is a human.

10. The method of claim 1 wherein the immune response is an aberrant, excessive or undesired immune response.

11. The method of claim 10 wherein the aberrant, excessive or undesired immune response is an autoimmune response.

12. A method of treating a disease or condition in an animal, said disease or condition being characterized by an aberrant, excessive or undesired immune response, comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid.

13. The method of claim 12 wherein the bioactive lipid is a sphingolipid or sphingolipid metabolite.

14. The method of claim 12 wherein the bioactive lipid is a lysolipid or lysolipid metabolite.

15. The method of claim 14 wherein the lysolipid is S1P, LPA or a variant of S1P or LPA.

16. The method of claim 12 wherein the agent is an antibody or antibody fragment.

17. The method of claim 16 wherein the antibody is a monoclonal antibody.

18. The method of claim 17 wherein the monoclonal antibody is a humanized monoclonal antibody.

19. The method of claim 12 wherein the animal is a human.

20. The method of claim 12 wherein the aberrant, excessive or undesired immune response is an autoimmune response.